+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Von Willebrand Disease Treatment Market by Product Type (Desmopressin, Hemostatic Agents, Replacement Therapies), Treatment Type (On Demand, Prophylaxis), End User, Distribution Channel, Severity - Global Forecast 2025-2030- Product Image
Von Willebrand Disease Treatment Market by Product Type (Desmopressin, Hemostatic Agents, Replacement Therapies), Treatment Type (On Demand, Prophylaxis), End User, Distribution Channel, Severity - Global Forecast 2025-2030- Product Image
Sale

Von Willebrand Disease Treatment Market by Product Type (Desmopressin, Hemostatic Agents, Replacement Therapies), Treatment Type (On Demand, Prophylaxis), End User, Distribution Channel, Severity - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5715686
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Von Willebrand Disease Treatment Market is evolving in response to clinical complexities and new therapy modalities, creating both challenges and opportunities for senior stakeholders seeking to optimize care pathways and investment strategies.

Market Snapshot: Von Willebrand Disease Treatment Market Overview

The Von Willebrand Disease Treatment Market grew from USD 718.76 million in 2024 to USD 804.82 million in 2025. It is expected to continue growing at a CAGR of 11.53%, reaching USD 1.38 billion by 2030. This upward trajectory is indicative of escalating demand for advanced therapies, evolving care models, and expanding access on a global scale. Progressive adoption across North America, Europe, Asia Pacific, and developing regions reflects ongoing commitment among health systems and industry players to address this rare but impactful bleeding disorder.

Scope & Segmentation

This report delivers a comprehensive analysis of evolving market dynamics, segmented as follows:

  • Product Type: Includes desmopressin (intranasal, intravenous), hemostatic agents (antifibrinolytics such as aminocaproic acid and tranexamic acid), and replacement therapies (plasma-derived and recombinant von Willebrand factor concentrates).
  • Treatment Type: On-demand interventions for acute and preprocedural needs, as well as continuous and intermittent prophylaxis.
  • End User: Clinics (outpatient, specialty), hemophilia treatment centers, and hospitals (public, private).
  • Distribution Channel: Hospital pharmacy, online pharmacy, and retail pharmacy (chain, independent outlets).
  • Severity: Encompasses cases ranging from Type 1 and Type 3 to all Type 2 subvariants (2A, 2B, 2M, 2N).
  • Geography: Strategic insights on the Americas (with US state-level detail), Europe, Middle East & Africa, and Asia-Pacific—capturing both established and high-growth regional markets.
  • Company Analysis: Tracks recent activity and outlook across leading firms including CSL Limited, Takeda, Octapharma AG, Grifols S.A., Laboratoire Français du Fractionnement et des Biotechnologies, Kedrion S.p.A., Bio Products Laboratory Limited, and Biotest AG.

Key Takeaways for Senior Decision-Makers

  • Individualized treatment pathways are increasingly essential, with the shift toward precision medicine enabling tailored approaches that address diverse bleeding phenotypes and patient lifestyles.
  • Next-generation therapeutic modalities such as gene therapy and long-acting recombinant concentrates are impacting both care delivery and patient adherence models.
  • Real-world data collection and patient registries provide new frameworks for evaluating long-term efficacy and informing clinical and payer decisions.
  • Integrated digital solutions, including telemedicine and remote monitoring, are supporting clinicians in delivering dynamic, data-driven disease management.
  • Collaboration between biopharma stakeholders, treatment centers, and advocacy organizations fosters education, access, and operational best practices in this complex landscape.

Tariff Impact: US Trade Policy Influences

New US tariffs on hemostatic agents and plasma-derived therapies, effective 2025, are forcing manufacturers and distributors to reevaluate their supply chain strategies. Companies with localized production may gain operational advantages, while those dependent on imports are likely to face margin pressures. This environment is prompting renegotiation of supplier contracts and cost-containment initiatives to ensure ongoing patient access and competitive pricing.

Methodology & Data Sources

This report is underpinned by a rigorous mixed-methods approach combining in-depth interviews with key experts—including hematologists, payers, patient advocates, and supply chain professionals—with exhaustive review of the peer-reviewed literature, regulatory filings, and clinical trials. Proprietary quantitative analyses were integrated with public data to triangulate insights, and regional sub-analysis provided context for variable infrastructure and policy environments.

Why This Report Matters

  • Delivers strategic clarity in a complex, fragmented market—supporting targeted investment, market entry, and partnering decisions.
  • Equips leadership with actionable intelligence on supply chain risks, tariff implications, and the evolving regulatory environment.
  • Supports differentiation by revealing trends in patient access, therapeutic innovation, and collaboration necessary for sustainable growth.

Conclusion

Senior decision-makers gain a focused view of how shifting therapies, supply chains, and patient-centric strategies are collectively shaping future opportunities in Von Willebrand Disease treatment. By leveraging these insights, organizations can better navigate complexities, mitigate risk, and create value for all stakeholders in this advancing field.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of gene therapy approaches for long term management of von Willebrand disease
5.2. Development and clinical integration of recombinant von Willebrand factor concentrates with extended half life
5.3. Expansion of prophylactic treatment protocols using extended half life von Willebrand factor products in severe patients
5.4. Advancements in personalized treatment strategies through pharmacogenomic profiling of von Willebrand disease patients
5.5. Growing investment in digital therapeutics and remote monitoring solutions for tracking bleeding episodes
5.6. Emergence of novel RNA interference based agents targeting excessive von Willebrand factor production in type 2A patients
5.7. Pressure on pricing and reimbursement frameworks amid introduction of biosimilar von Willebrand factor therapies
5.8. Surge in research on nanoformulation delivery platforms to enhance von Willebrand factor stability and bioavailability
5.9. Increasing focus on pediatric patient centric care models and specialized regimens for young von Willebrand disease patients
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Von Willebrand Disease Treatment Market, by Product Type
8.1. Introduction
8.2. Desmopressin
8.2.1. Intranasal
8.2.2. Intravenous
8.3. Hemostatic Agents
8.3.1. Antifibrinolytics
8.3.1.1. Aminocaproic Acid
8.3.1.2. Tranexamic Acid
8.4. Replacement Therapies
8.4.1. Plasma Derived Vwf Concentrates
8.4.2. Recombinant Vwf Concentrates
9. Von Willebrand Disease Treatment Market, by Treatment Type
9.1. Introduction
9.2. On Demand
9.2.1. Acute Treatment
9.2.2. Preprocedural Treatment
9.3. Prophylaxis
9.3.1. Continuous Prophylaxis
9.3.2. Intermittent Prophylaxis
10. Von Willebrand Disease Treatment Market, by End User
10.1. Introduction
10.2. Clinics
10.2.1. Outpatient Clinics
10.2.2. Specialty Clinics
10.3. Hemophilia Treatment Centers
10.4. Hospitals
10.4.1. Private Hospitals
10.4.2. Public Hospitals
11. Von Willebrand Disease Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
11.4.1. Chain Pharmacies
11.4.2. Independent Pharmacies
12. Von Willebrand Disease Treatment Market, by Severity
12.1. Introduction
12.2. Type 1
12.3. Type 2
12.3.1. Type 2A
12.3.2. Type 2B
12.3.3. Type 2M
12.3.4. Type 2N
12.4. Type 3
13. Americas Von Willebrand Disease Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Von Willebrand Disease Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Von Willebrand Disease Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. CSL Limited
16.3.2. Takeda Pharmaceutical Company Limited
16.3.3. Octapharma AG
16.3.4. Grifols, S.A.
16.3.5. Laboratoire Français du Fractionnement et des Biotechnologies
16.3.6. Kedrion S.p.A.
16.3.7. Bio Products Laboratory Limited
16.3.8. Biotest AG
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. VON WILLEBRAND DISEASE TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. VON WILLEBRAND DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. VON WILLEBRAND DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. VON WILLEBRAND DISEASE TREATMENT MARKET: RESEARCHAI
FIGURE 26. VON WILLEBRAND DISEASE TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 27. VON WILLEBRAND DISEASE TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 28. VON WILLEBRAND DISEASE TREATMENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. VON WILLEBRAND DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY AMINOCAPROIC ACID, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY AMINOCAPROIC ACID, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TRANEXAMIC ACID, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TRANEXAMIC ACID, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PLASMA DERIVED VWF CONCENTRATES, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PLASMA DERIVED VWF CONCENTRATES, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RECOMBINANT VWF CONCENTRATES, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RECOMBINANT VWF CONCENTRATES, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PREPROCEDURAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PREPROCEDURAL TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CONTINUOUS PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CONTINUOUS PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTERMITTENT PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTERMITTENT PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOPHILIA TREATMENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOPHILIA TREATMENT CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 1, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 1, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2A, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2A, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2B, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2B, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2M, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2M, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2N, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2N, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 3, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 3, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 173. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 174. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 175. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2024 (USD MILLION)
TABLE 176. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2025-2030 (USD MILLION)
TABLE 177. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2024 (USD MILLION)
TABLE 178. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2025-2030 (USD MILLION)
TABLE 179. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2024 (USD MILLION)
TABLE 180. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2025-2030 (USD MILLION)
TABLE 181. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2024 (USD MILLION)
TABLE 182. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2025-2030 (USD MILLION)
TABLE 183. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 184. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 185. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
TABLE 186. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2025-2030 (USD MILLION)
TABLE 187. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 188. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 189. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 192. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 193. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 194. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 195. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 198. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 199. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
TABLE 200. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2025-2030 (USD MILLION)
TABLE 201. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2024 (USD MILLION)
TABLE 202. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2025-2030 (USD MILLION)
TABLE 203. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 204. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 205. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2024 (USD MILLION)
TABLE 206. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2025-2030 (USD MILLION)
TABLE 207. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2024 (USD MILLION)
TABLE 208. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2025-2030 (USD MILLION)
TABLE 209. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2024 (USD MILLION)
TABLE 210. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2025-2030 (USD MILLION)
TABLE 211. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2024 (USD MILLION)
TABLE 212. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2025-2030 (USD MILLION)
TABLE 213. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 214. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 215. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
TABLE 216. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2025-2030 (USD MILLION)
TABLE 217. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 218. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 219. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 222. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 223. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 224. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 225. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 228. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 229. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
TABLE 230. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2025-2030 (USD MILLION)
TABLE 231. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2024 (USD MILLION)
TABLE 232. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 235. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2024 (USD MILLION)
TABLE 236. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2025-2030 (USD MILLION)
TABLE 237. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2024 (USD MILLION)
TABLE 238. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2025-2030 (USD MILLION)
TABLE 239. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2024 (USD MILLION)
TABLE 240. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2025-2030 (USD MILLION)
TABLE 241. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2024 (USD MILLION)
TABLE 242. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2025-2030 (USD MILLION)
TABLE 243. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 244. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 245. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
TABLE 246. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2025-2030 (USD MILLION)
TABLE 247. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 248. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 249. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 252. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 253. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 254. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 255. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 258. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 259. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
TABLE 260. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2025-2030 (USD MILLION)
TABLE 261. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2024 (USD MILLION)
TABLE 262. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2025-2030 (USD MILLION)
TABLE 263. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 264. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 265. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2024 (USD MILLION)
TABLE 266. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2025-2030 (USD MILLION)
TABLE 267. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2024 (USD MILLION)
TABLE 268. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2025-2030 (USD MILLION)
TABLE 269. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2024 (USD MILLION)
TABLE 270. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2025-2030 (USD MILLION)
TABLE 271. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2024 (USD MILLION)
TABLE 272. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2025-2030 (USD MILLION)
TABLE 273. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 274. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 275. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
TABLE 276. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2025-2030 (USD MILLION)
TABLE 277. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 278. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 279. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 282. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 283. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 284. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 285. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 288. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 289. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
TABLE 290. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2025-2030 (USD MILLION)
TABLE 291. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2024 (USD MILLION)
TABLE 292. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2025-2030 (USD MILLION)
TABLE 293. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 294. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 295. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2024 (USD MILLION)
TABLE 296. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2025-2030 (USD MILLION)
TABLE 297. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2024 (USD MILLION)
TABLE 298. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2025-2030 (USD MILLION)
TABLE 299. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2024 (USD MILLION)
TABLE 300. EUROPE, MIDD

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Von Willebrand Disease Treatment market report include:
  • CSL Limited
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Grifols, S.A.
  • Laboratoire Français du Fractionnement et des Biotechnologies
  • Kedrion S.p.A.
  • Bio Products Laboratory Limited
  • Biotest AG

Table Information

Report AttributeDetails
No. of Pages184
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 804.82 Million
Forecasted Market Value ( USD ) by 2030 $ 1380 Million
Compound Annual Growth Rate11.5%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Von Willebrand Disease Market Report 2025 - Product Image

Von Willebrand Disease Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Von Willebrand's Disease - Pipeline Insight, 2025 - Product Image

Von Willebrand's Disease - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Bleeding Disorders Treatment Market Report and Forecast 2025-2034 - Product Image

Bleeding Disorders Treatment Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Coagulation Factor Concentrates Market by Product Type (Plasma Derived, Recombinant), Indication (Hemophilia A, Hemophilia B, Von Willebrand Disease), Formulation, End User, Distribution Channel, Route Of Administration - Global Forecast 2025-2030 - Product Image

Coagulation Factor Concentrates Market by Product Type (Plasma Derived, Recombinant), Indication (Hemophilia A, Hemophilia B, Von Willebrand Disease), Formulation, End User, Distribution Channel, Route Of Administration - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Von Willebrand Disease. Basic and Clinical Aspects. Edition No. 1 - Product Image

Von Willebrand Disease. Basic and Clinical Aspects. Edition No. 1

  • Book
  • 268 Pages

About the Von Willebrand Disease Drug Market

Von Willebrand Disease (VWD) is a rare inherited bleeding disorder caused by a deficiency or defect in the von Willebrand factor (VWF). The von Willebrand Disease Drug market is a subset of the Hematological Drugs market, which includes drugs used to treat blood-related disorders. VWD drugs are used to treat the symptoms of VWD, such as excessive bleeding, and to prevent bleeding episodes. These drugs are typically administered intravenously or subcutaneously, and may include desmopressin, antifibrinolytics, and recombinant VWF. The Von Willebrand Disease Drug market is highly competitive, with several major players. These include Shire, Pfizer, Novo Nordisk, CSL Behring, and Bayer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.